Your browser doesn't support javascript.
loading
Coronavirus disease 2019 and lung cancer: where are we?
Ocanto, Abrahams; Mielgo-Rubio, Xabier; Luna Tirado, Javier; Linares Mesa, Nuria; López Valcárcel, Marta; Pedraza, Sara; Barragan, Victoria Vera; Nieto, Patricia Valencia; Martín, Juan Zafra; Couñago, Felipe.
Afiliação
  • Ocanto A; Department of Radiation Oncology, Hospital Universitario San Francisco de Asís, GenesiCare Madrid, 28002 Madrid, Spain.
  • Mielgo-Rubio X; Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesiCare Madrid, 28002 Madrid, Spain.
  • Luna Tirado J; Department of Medical Oncology, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain.
  • Linares Mesa N; Department of Radiation Oncology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain.
  • López Valcárcel M; Department of Radiation Oncology, Hospital Universitario Juan Ramón Jiménez, 21005 Huelva, Spain.
  • Pedraza S; Department of Radiation Oncology, Hospital Universitario Puerta de Hierro, 28222 Madrid, Spain.
  • Barragan VV; Department of Radiation Oncology, Hospital Universitario 12 de Octubre Madrid, 28041 Madrid, Spain.
  • Nieto PV; Department of Radiation Oncology, Hospital Universitario de Badajoz, 06080 Badajoz, Spain.
  • Martín JZ; Department of Radiation Oncology, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain.
  • Couñago F; Group of Translational Research in Cancer Immunotherapy, Centro de Investigaciones Médico-Sanitarias (CIMES), Universidad de Málaga (UMA), Instituto de Investigación Biomédica de Málaga (IBIMA), 29010 Málaga, Spain.
Explor Target Antitumor Ther ; 4(5): 1082-1094, 2023.
Article em En | MEDLINE | ID: mdl-38023992
ABSTRACT
Oncology patients are more susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection due to hospital contact and an immunological system that can be compromised by antineoplastic therapy and supportive treatments. Certain similarities have been described in the physiopathology of coronavirus disease 2019 (COVID-19) and lung cancer (LC) that may explain the higher probability of these patients of developing a more serious disease with more frequent hospitalizations and even death, especially with the addition of smoking, cardiovascular and respiratory comorbidities, old age and corticosteroids use. Pre-existing lesions and cancer therapies change the normal architecture of the lungs, so diagnostic scales such as COVID-19 Reporting and Data System (CO-RADS) are of vital importance for a correct diagnosis and patient homogenization, with a high inter-observer correlation. Moreover, anticancer treatments have required an adaptation to reduce the number of visits to the hospital [hypofractionated radiotherapy (RT), larger intervals between chemotherapy cycles, delay in follow-up tests, among others]. In a way, this has also caused a delay in the diagnosis of new cancers. On the other hand, vaccination has had a positive impact on the mortality of these patients, who maintain a similar seroprevalence to the rest of the population, with a similar impact in mortality.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Explor Target Antitumor Ther Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Explor Target Antitumor Ther Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha